Posts for BIONOMICS LIMITED/FI ($BNOX)

Explore Neuphoria Therapeutics Inc.'s Q4 2024 financial performance, highlighting net losses, liquidity issues, and strategic partnerships. A hold recommendation is advised.

Explore the latest 8-K filing from Neuphoria Therapeutics Inc. detailing significant corporate updates as of January 10, 2025. Stay informed on potential impacts for investors.

Explore Bionomics Limited's recent 8-K filing detailing significant events, stock info, and compliance updates as of December 23, 2024. Stay informed for investment decisions.